This month's 11 percent drop in the iShares Nasdaq Biotechnology ETF has investors worried if the "biotech bubble" is bursting. But is it too soon to give up on a sector that's up 250 percent in the last five years?
One biotech CEO isn't worried about the pressure on the sector. Acceleron's Dr. John Knopf said on Thursday's edition of CNBC's "Fast Money," "We just like to focus on our products and develop our products."
"The clinical folks like the data and so do the medical community, and we expect to present more data this June," he added.
Check out what Acceleron has coming down the pipeline in "Fast Money's" interview with the founder & CEO of Acceleron.